A randomised phase 2 study of intermittent versus continuous dosing of dabrafenib plus trametinib in patients with BRAFV600 mutant advanced melanoma (INTERIM)

Autor:	Dayimu, Alimu, Gupta, Avinash, Matin, Rubeta N., Nobes, Jenny, Board, Ruth, Payne, Miranda, Rao, Ankit, Fusi, Alberto, Danson, Sarah, Eccles, Bryony, Carser, Judith, Brown, Ciara O’Hanlon, Steven, Neil, Bhattacharyya, Madhumita, Brown, Ewan, Gonzalez, Michael, Highley, Martin, Pickering, Lisa, Kumar, Satish, Waterston, Ashita, Burghel, George, Demain, Leigh, Baker, Eleanor, Wulff, Jerome, Qian, Wendi, Twelves, Sophie, Middleton, Mark, Corrie, Pippa
Zdroj:	In European Journal of Cancer January 2024 196
Databáze:	ScienceDirect
Externí odkaz:	Zobrazit plný text záznamu Full Text from ScienceDirect